IMMP

Immutep Limited [IMMP] Stock Forecast

Q: What is Immutep Limited stock symbol ?

Immutep Limited is a AU stock, located in Sydney of Nsw and trading under the symbol IMMP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

IMMP Stock Summary

Earnings have grown 1957.72% per last year.

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 33.53%

Earnings are expected to fall -100% next year

IMMP has less than 1 year of cash runway

Top 10 Correlated Stocks

IMMP

In the News

IMMP Financial details

Company Rating

Neutral

Market Cap

282.97M

Income

-77.07M

Revenue

3.68M

Book val./share

0.1

Cash/share

0.09

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

28 Aug 2024

P/E

Forward P/E

PEG

P/S

P/B

P/C

24.89

P/FCF

-9.76

Quick Ratio

13.45

Current Ratio

13.81

Debt / Equity

0.01

LT Debt / Equity

0.01

EPS (TTM)

-0.08

EPS next Y

EPS next Q

EPS this Y

19.52%

EPS next Y

EPS next 5Y

EPS last 5Y

-1.94%

Revenue last 5Y

90.49%

Revenue Q/Q

EPS Q/Q

-15.17%

SMA20

SMA50

SMA100

Inst Own

0.6%

Inst Trans

0.33%

ROA

ROE

ROC

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.5-3.9

52W High

-25.33%

52W Low

+124%

RSI

Rel Volume

0.21

Avg Volume

137.84K

Volume

28.97K

Perf Week

-11.46%

Perf Month

-18.55%

Perf Quarter

19.79%

Perf Half Y

22.4%

Beta

1.83

Volatility

0.09%, 0.16%

Prev Close

1.82%

Price

2.24

Change

-0.44%

IMMP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-06-30

Metric	2019-06-30	2020-06-30	2021-06-30	2022-06-30	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0.02	0.01	0	0
Net income per share	-0.05	-0.03	-0.05	-0.04	-0.04
Operating cash flow per share	-0.05	-0.03	-0.03	-0.04	-0.04
Free cash flow per share	-0.05	-0.03	-0.03	-0.04	-0.04
Cash per share	0.05	0.06	0.1	0.09	0.14
Book value per share	0.07	0.08	0.12	0.11	0.15
Tangible book value per share	0.02	0.04	0.1	0.1	0.14
Share holders equity per share	0.07	0.08	0.12	0.11	0.15
Interest debt per share	0.02	0.02	0	0	0
Market cap	814.38M	636.17M	3.13B	2.57B	2.84B
Enterprise value	805.45M	618.9M	3.07B	2.49B	2.72B
P/E ratio	-50.05	-47.24	-104.69	-79.72	-71.3
Price to sales ratio	5.83K	84.98	788.88	15.07K	811.38
POCF ratio	-53.27	-58.69	-177.46	-84.94	-79.27
PFCF ratio	-53.13	-58.59	-177.3	-84.88	-79.17
P/B Ratio	33.39	19.1	42.72	27.29	20.84
PTB ratio	33.39	19.1	42.72	27.29	20.84
EV to sales	5.76K	82.67	774.44	14.61K	776.53
Enterprise value over EBITDA	-43.45	-44.4	-148.3	-78.1	-63.49
EV to operating cash flow	-52.69	-57.1	-174.21	-82.35	-75.87
EV to free cash flow	-52.55	-57	-174.05	-82.29	-75.77
Earnings yield	-0.02	-0.02	-0.01	-0.01	-0.01
Free cash flow yield	-0.02	-0.02	-0.01	-0.01	-0.01
Debt to equity	0.31	0.27	0.04	0.02	0.01
Debt to assets	0.19	0.19	0.03	0.02	0.01
Net debt to EBITDA	0.48	1.24	2.77	2.46	2.85
Current ratio	4.44	9.26	12.81	14.16	13.81
Interest coverage	0	-1.53K	-1.99K	-367.17	-2.2K
Income quality	0.83	0.8	0.59	0.94	0.9
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	43.85	0.85	1.58	42.32	2.48
Research and developement to revenue	118.69	2.72	4.34	183.96	8.21
Intangibles to total assets	0.42	0.33	0.16	0.1	0.06
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	-0.3	0	0	-0.13	-0.01
Capex to depreciation	-0.02	-0.01	-0.01	-0.01	-0.02
Stock based compensation to revenue	11.32	0.23	0.43	8.73	0.57
Graham number	0.29	0.25	0.37	0.3	0.39
ROIC	-0.57	-0.38	-0.26	-0.35	-0.33
Return on tangible assets	-0.69	-0.43	-0.43	-0.35	-0.29
Graham Net	0.01	0.04	0.09	0.09	0.13
Working capital	18.24M	27.79M	63.08M	84.4M	125.19M
Tangible asset value	7.44M	18.1M	60.42M	83.52M	126.98M
Net current asset value	7.39M	17.85M	59.66M	82.72M	123.99M
Invested capital	0.31	0.27	0.04	0.02	0.01
Average receivables	4.36M	4.31M	4.76M	7.25M	8.17M
Average payables	2.09M	2.1M	1.73M	2.35M	4.16M
Average inventory	1	1	-2.83M	-3.38M	-554.16K
Days sales outstanding	13.66K	165.36	563.34	17.94K	830.13
Days payables outstanding	56.26	26.63	321.76	506.98	964.49
Days of inventory on hand	0	0	-997.86	-196.05	0
Receivables turnover	0.03	2.21	0.65	0.02	0.44
Payables turnover	6.49	13.71	1.13	0.72	0.38
Inventory turnover	16.59M	22.47M	-0.37	-1.86	1.03M
ROE	-0.67	-0.4	-0.41	-0.34	-0.29
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q2

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.02	0	-0.02	0	-0.02
Operating cash flow per share	-0.01	0	-0.01	0	0
Free cash flow per share	-0.01	0	-0.01	0	0
Cash per share	0.08	0	0.14	0	0.09
Book value per share	0.09	0	0.15	0	0.1
Tangible book value per share	0.08	0	0.14	0	0.09
Share holders equity per share	0.09	0	0.15	0	0.1
Interest debt per share	0	0	0	0	0
Market cap	2.28B	0	2.91B	0	4.18B
Enterprise value	2.21B	0	2.79B	0	4.08B
P/E ratio	-27.63	0	-37.75	0	-49.19
Price to sales ratio	1.35K	0	1.6K	0	0
POCF ratio	-409.27	0	-348.69	0	-761
PFCF ratio	-404.52	0	-348.57	0	-760.03
P/B Ratio	29.72	0	21.33	0	36.12
PTB ratio	29.72	0	21.33	0	36.12
EV to sales	1.31K	0	1.53K	0	0
Enterprise value over EBITDA	-99.75	0	-133.37	0	-168.09
EV to operating cash flow	-397.16	0	-334.05	0	-742.4
EV to free cash flow	-392.55	0	-333.93	0	-741.45
Earnings yield	-0.01	0	-0.01	0	-0.01
Free cash flow yield	0	0	0	0	0
Debt to equity	0.01	0	0.01	0	0.01
Debt to assets	0.01	0	0.01	0	0.01
Net debt to EBITDA	3.04	0	5.84	0	4.21
Current ratio	8.97	0	13.81	0	17.24
Interest coverage	-1.54K	0	-4.03K	0	-2.34K
Income quality	0.27	0	0.43	0	0.26
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.45	0	2.5	0	0
Research and developement to revenue	11.26	0	5.39	0	0
Intangibles to total assets	0.12	0	0.06	0	0.07
Capex to operating cash flow	0.01	0	0	0.03	0
Capex to revenue	-0.04	0	0	0	0
Capex to depreciation	-0.07	0	0	0	-0.01
Stock based compensation to revenue	0	0	1.1	0	0
Graham number	0.21	0	0.27	0	0.2
ROIC	-0.3	0	-0.16	0	-0.22
Return on tangible assets	-0.27	0	-0.14	0	-0.18
Graham Net	0.07	0	0.13	0	0.08
Working capital	66.84M	0	125.19M	0	106.48M
Tangible asset value	66.68M	0	126.98M	0	106.9M
Net current asset value	65.9M	0	123.99M	0	104.89M
Invested capital	0.01	0	0.01	0	0.01
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	266.73	0	394.24	0	0
Days payables outstanding	756.75	0	530.66	0	274.19
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0.34	0	0.23	0	0
Payables turnover	0.12	0	0.17	0	0.33
Inventory turnover	935.2K	0	462.01K	0	0
ROE	-0.27	0	-0.14	0	-0.18
Capex per share	0	0	0	0	0

IMMP Frequently Asked Questions

What is Immutep Limited stock symbol ?

Immutep Limited is a AU stock , located in Sydney of Nsw and trading under the symbol IMMP

What is Immutep Limited stock quote today ?

Immutep Limited stock price is $2.24 today.

Is Immutep Limited stock public?

Yes, Immutep Limited is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 137.84K
Market Capitalization 282.97M
Employee 41
CEO Mr. Marc Voigt
Headquarters Sydney,NSW,AU
IPO Date 2012-04-19
Website https://www.immutep.com

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.